A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer

Overview of attention for article published in Redox Biology, October 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 2,687)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 24 news outlets
blogs: 4 blogs
twitter: 301 X users
facebook: 2 Facebook pages

reddit: 6 Redditors
video: 1 YouTube creator
bluesky: 10 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 338 X posts from 301 X users, with an upper bound of 11,189,564 followers.

@MattZirwas Agree that study doesn’t prove much. But this one does: IV ascorbate w/chemo at 75g 3x/week for metastatic pancreatic cancer: doubled survival similar to the new RAS drug. https://t.co/7XCmXxjwnr https://t.co/KvRUULvWD3

@YannickBuccella My dad died from stage 4 pancreatic cancer. This high dose ascorbate trial also looks promising—doubled survival rates. https://t.co/7XCmXxjwnr https://t.co/v3fISD9vpD

A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. @IowaMed https://t.co/hwLFkbVUWH https://t.co/3eQP5OAur3

Adding 75 grams of intravenous Vitamin C to standard chemotherapy (gemcitabine and nab-paclitaxel) doubled overall survival from 8.3 months to 16 months for patients with stage IV metastatic pancreatic cancer. https://t.co/3MC5pero2f

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 334 additional X posts.